Your Messages Inbox
Your Article Summary
See Latest ArticlesBayer Schering Pharma collaborates with AC Immune in the field of Alzheimer's disease
BayNews International, 10/15/09
Bayer Schering Pharma AG, Germany, will provide its development candidate florbetaben, a so called PET (positron emission tomography) tracer, to the Swiss–based biopharmaceutical company AC Immune SA, to support a clinical trial in the field of Alzheimer´s disease (AD). This study is conducted to develop a therapy option for the treatment of AD. Bayer´s novel PET tracer florbetaben will be applied for imaging of beta–Amyloid deposition in the brain of patients undergoing the phase I clinical testing of AC Immune´s Alzheimer´s vaccine ACI–24.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
BayNews International, 12/04/09
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
Sanofi-aventis, 12/04/09
Watson Receives FTC Clearance for Arrow Acquisition
Watson Pharmaceuticals, 12/03/09
Article Search
Sponsor